Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Indole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.44 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 7/20 | 0.94 |
| ▸ | CA1 | P00915 | 2/20 | 0.94 |
| ▸ | CA4 | P22748 | 2/20 | 0.94 |
| ▸ | CA6 | P23280 | 2/20 | 0.94 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.94 |
| ▸ | CA2 | P00918 | 1/20 | 0.94 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.94 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.94 |
| ▸ | ITGAL | P20701 | 1/20 | 0.94 |
| ▸ | ADK | P55263 | 1/20 | 0.94 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indole SCHEMBL4364385 | 1.00 | AHR (0.94) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL29418271 | 1.00 | AHR (0.94) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL29800701 | 0.97 | AHR (0.90) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL9215713 | 0.97 | AHR (0.90) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL9215718 | 0.97 | AHR (0.90) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL27455365 | 0.97 | AHR (0.90) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL30250492 | 0.97 | — | — | |
| Indole SCHEMBL29352896 | 0.97 | — | — | |
| Indole SCHEMBL30463845 | 0.97 | — | — | |
| Indole SCHEMBL698 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164958-A | Indole ether compound and preparation method thereof | 周口师范学院 | 2024-06-11 | — | — | CN | claimed |
| US-20030229069-A1 | 1-Sulfonyl-4-aminoalkoxy indole derivatives and uses thereof | ROCHE PALO ALTO LLC | 2003-12-11 | — | — | US | claimed |
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118164958-A | Indole ether compound and preparation method thereof | 周口师范学院 | 2024-06-11 | — | — | CN | disclosed |
| CN-118164958-A | Indole ether compound and preparation method thereof | 周口师范学院 | 2024-06-11 | — | — | CN | disclosed |
| CN-111527080-B | Substituted indole ether compounds | 百时美施贵宝公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-111527080-B | Substituted indole ether compounds | 百时美施贵宝公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-109564213-B | Detecting microbial wound infection | 西诺福有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20210070751-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-11 | — | — | US | disclosed |
| US-20040186114-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | US | disclosed |
| US-6774241-B2 | HT3 RECEPTOR ANTAGONISTS FOR NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, AND SLEEP DISORDER TREATMENT | ROCHE PALO ALTO LLC | 2004-08-10 | — | — | US | disclosed |
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | ROCHE PALO ALTO LLC (US) | 2004-07-08 | — | — | US | disclosed |
| WO-2004050085-A1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003104193-A1 | 1-SULFONYL-4-AMINOALKOXY INDOLE DERIVATIVES AS 5-HT6-RECEPTOR MODULATORS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-18 | — | — | WO | disclosed |
| US-20030229069-A1 | 1-Sulfonyl-4-aminoalkoxy indole derivatives and uses thereof | ROCHE PALO ALTO LLC | 2003-12-11 | — | — | US | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186114-A1 | Cytokine inhibitors | IL1A, IL1B, IL1R1 | PARP1 356/4885MEN1 2239/4885AHR 879/4885 |
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | HTR3C, HTR2C, CYP3A5 | PARP1 780/4885MEN1 1098/4885AHR 276/4885 |
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | PARP1 147/4885MEN1 2898/4885AHR 448/4885 |
| US-20210070751-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | TLR7, TLR8, TLR1 | PARP1 875/4885MEN1 3173/4885AHR 79/4885 |
| US-20030229069-A1 | 1-Sulfonyl-4-aminoalkoxy indole derivatives and uses thereof | IDO1, TPH1, SLC6A4 | PARP1 2071/4885MEN1 1398/4885AHR 264/4885 |
| US-12030878-B2 | Substituted indole ether compounds | TLR7, TLR8, TLR1 | PARP1 875/4885MEN1 3173/4885AHR 79/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | PARP1 3123/4885MEN1 1653/4885AHR 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.